

Curriculum Vitae Stefanie Hahner

Personal Data

Title	Prof. Dr. med.
First name	Stefanie
Name	Hahner
Current position	Deputy Head of Division (permanent)
Current institution(s)/site(s), country	Division of Endocrinology and Diabetology, University Hospital Würzburg (UKW), Germany
Identifiers/ORCID	0000-0003-1616-8986

Selection of peer-reviewed research articles:

1. **Hahner S**, Hartrampf P, Beuschlein F, *et int*, Schirbel A, for the FAMIAN investigators. Combined [¹⁸F]Fluorodeoxyglucose PET and [¹²³I] Iodometomidate-SPECT for diagnostic evaluation of indeterminate adrenal neoplasias—the cross-sectional diagnostic test accuracy study FAMIAN. *eBioMedicine* 2025 Jun;116:105735. doi: 10.1016/j.ebiom.2025.105735
2. Schloetelburg W, Hartrampf PE, Kosmala A, *et int*, **Hahner S**. Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma. *Eur J Nucl Med Mol Imaging*. 2024 Oct;51(12):3643-3650. doi: 10.1007/s00259-024-06800-z.
3. Baudin E, Goichot B, Berruti A, *et int*, **Hahner S**, *et int*, Fassnacht M; ENDOCAN-COMETE; ENSAT Networks. Sunitinib for metastatic progressive pheochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. *Lancet*. 2024 Mar 16;403(10431):1061-1070. doi: 10.1016/S0140-6736(23)02554-0.
4. Terzolo M, Fassnacht M, Perotti P, *et int*, **Hahner S**, *et int*, Berruti A. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. *Lancet Diabetes Endocrinol*. 2023 Oct;11(10):720-730. doi: 10.1016/S2213-8587(23)00193-6.
5. **Hahner S**, Hartrampf PE, Mihatsch PW, *et int*, Schirbel A. Targeting 11-Beta Hydroxylase With [¹³¹I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma. *J Clin Endocrinol Metab*. 2022 Mar 24;107(4):e1348-e1355. doi: 10.1210/clinem/dgab895.
6. Heinze B, Schirbel A, Nannen L, *et int*, **Hahner S**. Novel CYP11B-ligand [¹²³I]/[¹³¹I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. *Eur J Nucl Med Mol Imaging*. 2021 Dec;49(1):301-310. doi: 10.1007/s00259-021-05477-y.
7. **Hahner S**, Ross RJ, Arlt W, *et int*, Quinkler M. Adrenal insufficiency. *Nat Rev Dis Primers*. 2021 Mar 11;7(1):19. doi: 10.1038/s41572-021-00252-7.
8. Burger-Stritt S, Eff A, Quinkler M, *et int*, **Hahner S**. Standardised patient education in adrenal insufficiency: a prospective multi-centre evaluation. *Eur J Endocrinol*. 2020 Aug;183(2):119-127. doi: 10.1530/EJE-20-0181.
9. Burger-Stritt S, Bachmann L, Kurlbaum M, **Hahner S**. Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. *Endocr Connect*. 2019 Apr 1;8(4):425-434. doi: 10.1530/EC-19-0024.
10. Heinze B, Fuss CT, Mulatero P, *et int*, **Hahner S**. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. *Hypertension*. 2018 Feb;71(2):317-325. doi: 10.1161/HYPERTENSIONAHA.117.09975.